C12-TLRa

• CAT Number: I040994
• Molecular Formula: C46H73N5O2
• Molecular Weight: 728.10
• Purity: ≥95%
• Synonyms: 1-[[4-[(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)methyl]phenyl]methyl-(2-hydroxydodecyl)amino]dodecan-2-ol
• InChI: InChI=1S/C46H73N5O2/c1-4-7-10-12-14-16-18-20-24-39(52)35-50(36-40(53)25-21-19-17-15-13-11-8-5-2)33-37-29-31-38(32-30-37)34-51-43(28-9-6-3)49-44-45(51)41-26-22-23-27-42(41)48-46(44)47/h22-23,26-27,29-32,39-40,52-53H,4-21,24-25,28,33-36H2,1-3H3,(H2,47,48)
• InChIKey: HIHJXHDBDZYVSP-UHFFFAOYSA-N
• SMILES: CCCCCCCCCCC(CN(CC1=CC=C(C=C1)CN2C(=NC3=C2C4=CC=CC=C4N=C3N)CCCC)CC(CCCCCCCCCC)O)O

C12-TLRa(CAT: I040994) is a synthetic Toll-like receptor (TLR) agonist, designed for innate immune system research. It selectively activates TLR signaling pathways, making it a valuable tool for studying immune modulation, inflammation, and host-pathogen interactions. C12-TLRa is particularly useful in cancer immunotherapy, infectious disease research, and vaccine adjuvant development. Its lipid-based structure (C12) enhances cellular uptake and bioavailability, optimizing its effectiveness in biochemical, cellular, and in vivo studies. Suitable for investigating immune responses and therapeutic interventions, this compound is for research use only; not for human or clinical applications.